BC Extra | Sep 3, 2019
Clinical News

Sept. 3 Clinical Quick Takes: Phase II failure for Aridis, plus Kura, Idorsia, Concert, PegBio

Aridis discontinuing antibacterial mAb   Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) said AR-105 plus standard of care antibiotics missed the primary endpoint of superiority to antibiotics alone in a Phase II trial to treat ventilator-associated pneumonia (VAP)...
BC Week In Review | Jan 18, 2016
Clinical News

Aerucin: Phase I data

An open-label, U.S. Phase I trial in 16 healthy volunteers showed that single ascending doses of <=20 mg/kg IV Aerucin led to no serious adverse events. This year, Aridis plans to start an international Phase...
BC Week In Review | Aug 3, 2015
Clinical News

Aerucin regulatory update

FDA granted Fast Track designation to Aridis’ Aerucin to treat hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. The human IgG1 mAb against P. aeruginosa is in Phase I testing, with data expected next quarter....
BC Week In Review | Apr 13, 2015
Clinical News

Aerucin: Phase I started

Aridis began an open-label, U.S. Phase I trial to evaluate single ascending doses of IV Aerucin in about 15 healthy adults. Aridis Pharmaceuticals Inc. , San Jose, Calif.   Product: Aerucin   Business: Infectious   Molecular...
BC Week In Review | May 27, 2013
Company News

Aridis, Kenta deal

Aridis Pharmaceuticals LLC , San Jose, Calif.   Kenta Biotech Ltd. , Schlieren, Switzerland   Business: Infectious   Infectious disease company Aridis will acquire Kenta's portfolio of six anti-infective human mAbs and technologies for an undisclosed cash...
Items per page:
1 - 5 of 5